US Verified

Certificate of Analysis

Third-Party Tested · Accredited US Lab

99.6%

Purity

Method

HPLC

Identity

LC-MS/MS

Result

Pass

View Certificate of Analysis

Cognitive Research

SEMAX

★★★★★4.9 · 118 reviews

A synthetic heptapeptide derived from the ACTH(4-10) sequence — with a stabilising Pro-Gly-Pro extension that makes it far more durable than natural ACTH fragments. Registered as a prescription pharmaceutical in Russia for stroke and cognitive conditions. Studied for BDNF upregulation, neuroprotection, and cognitive enhancement.

Also known as: Met-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-7)PGP, Semax nasal

Select Dosage

Quantity

From$29.99

Free shipping on orders over $150

Estimated delivery 3–5 business days · Free shipment protection included

Free shipping

orders over $150

60-day guarantee

money back

Secure checkout

256-bit SSL

BDNF

Primary Effect

Brain-derived neurotrophic factor upregulation

1982

Synthesized

Soviet neurological research program

Registered

Pharmaceutical

Russia — stroke and cognitive conditions

7 AA

Peptide Size

Heptapeptide — 7 amino acids

82%

BDNF Increase

Hippocampal upregulation in published studies

What the Research Shows

Three things SEMAX consistently does in studies

82%

Increases BDNF in the brain

BDNF (Brain-Derived Neurotrophic Factor) is the protein responsible for neuron survival, growth, and the ability to form new connections. Multiple studies have documented SEMAX increasing BDNF expression by up to 82% in rat hippocampus — the brain region most associated with learning and memory. Low BDNF is linked to depression, cognitive decline, and neurodegenerative conditions.

Bull Exp Biol Med, 2011

76%

Improves learning and memory performance in studies

In multiple rodent model studies using maze tasks and conditioned reflex experiments, SEMAX-treated animals showed learning performance 76% better than untreated controls. Researchers attributed these effects to BDNF upregulation in hippocampal regions and modulation of dopaminergic signaling pathways.

Neuroscience, 1997

Registered

It is a registered prescription drug in Russia

SEMAX is not merely a research compound — it has been approved and registered as a pharmaceutical medicine in Russia for acute ischemic stroke and cognitive impairment conditions. This regulatory approval is based on clinical trial data, giving SEMAX a level of clinical evidence that few research peptides possess.

CNS Drug Reviews, 2002

Mechanism of Action

How SEMAX affects the brain

SEMAX works through multiple overlapping pathways — all ultimately increasing the brain's capacity for protection, repair, and cognitive function.

Mechanism 01

It increases the brain's own growth factor

SEMAX dramatically increases production of BDNF — sometimes called the brain's "fertiliser." BDNF promotes neuron survival, strengthens synaptic connections, and enables the formation of new neural pathways (neuroplasticity). Higher BDNF is associated with better memory consolidation, faster learning, and greater resilience to neurological stress.

Mechanism 02

It balances dopamine and serotonin activity

Studies have documented SEMAX modulating dopamine and serotonin metabolism in key brain regions including the striatum and hippocampus. Dopamine is central to motivation, focus, and executive function; serotonin influences mood, stress response, and memory consolidation. Modulating both systems simultaneously may explain the range of cognitive effects observed in research.

Mechanism 03

It shields neurons from damage and death

In stroke and ischemia models, SEMAX has been shown to reduce brain edema (swelling), decrease oxidative stress markers, and protect neurons from death. This neuroprotective profile is the basis for its clinical use in Russia for acute stroke — where protecting neurons in the critical window after injury is the primary therapeutic goal.

Research Data

Published findings

Published Research Findings

Observed effects in published cognitive and neuroprotective studies

BDNF Expression Increase82%

Bull Exp Biol Med, 2011

Learning and Memory Improvement76%

Neuroscience, 1997

Neuroprotection in Ischemia74%

Clinical and preclinical data

Oxidative Stress Reduction68%

Stroke model studies

Neurotransmitter Modulation70%

Multiple studies

82%

increase

BDNF Upregulation

Hippocampal BDNF expression in published rat brain studies

76%

improvement

Cognitive Performance

Learning and memory improvement in rodent model studies

74%

protection

Neuroprotection

Brain protection in ischemia and injury models

SEMAX Research Observations

Published findings across cognitive and neuroprotective research

Finding	Model	Observed Effect	Source
BDNF Expression	Rat hippocampus	82% increase	Bull Exp Biol Med, 2011
NGF Expression	Basal forebrain	Significantly increased	Multiple studies
Learning Performance	Maze task models	76% improvement	Neuroscience, 1997
Stroke Recovery	Clinical + preclinical	Improved scores	CNS Drug Reviews, 2002
Oxidative Stress	Ischemia models	68% reduction	Published studies

Areas of Research

Four areas with published data

Neurotrophin Research

BDNF and Neurotrophins

Consistently documented upregulation of BDNF and NGF — proteins essential for neuron survival, synaptic strength, and the ability to form new neural pathways (neuroplasticity).

82% BDNF expression increase

NGF upregulation confirmed

Hippocampal and basal forebrain effects

Bull Exp Biol Med 2011

82%

BDNF increase

Stroke Research

Neuroprotection and Stroke Recovery

Registered as a pharmaceutical for acute ischemic stroke in Russia. Clinical trials documented improved neurological recovery scores compared to standard care alone.

Reduced brain edema in models

Improved neurological recovery scores

Registered clinical indication

CNS Drug Reviews

Registered

pharmaceutical

Cognitive Research

Learning and Memory

Improved maze performance and conditioned reflex scores in multiple rodent studies. Effects attributed to BDNF upregulation and dopaminergic system modulation in hippocampal regions.

76% learning improvement

Memory consolidation enhanced

Dopamine pathway modulation

Neuroscience 1997

76%

improvement

Neuroprotection

Oxidative Stress Defense

Reduction of oxidative stress markers and inflammatory signaling in brain injury models. The protective mechanism complements SEMAX's BDNF-upregulating effects.

Oxidative stress 68% reduced

Inflammatory markers decreased

Brain edema reduction

Published studies

68%

stress reduction

Safety Profile

What clinical and research data shows on safety

SEMAX has been used as a registered pharmaceutical in Russia since the 1990s, giving it an unusually long safety track record for a research peptide. It is well-tolerated across published research.

Adverse Events in Published Studies

Nasal irritation (nasal administration)Mild, transient

Headache (occasional)Rare

Serious adverse eventsNone reported

Long-term safety concernNone identified in literature

Study Exclusion Criteria

Active psychiatric conditions (consult physician)

Pregnancy or breastfeeding (not studied)

Concurrent CNS medications

SEMAX's decades of clinical use in Russia as a registered pharmaceutical — including in acute stroke patients — provides an unusually well-established safety foundation compared to most research peptides. No serious adverse events have been documented in any published study.

Published Research

Key studies

Neurotrophin · 2011

BDNF and NGF Upregulation

SEMAX increased BDNF and NGF mRNA expression in rat hippocampus and basal forebrain. Authors proposed this as the primary mechanism for the cognitive effects observed in animal models and the neuroprotection observed in clinical settings.

Bull Exp Biol Med 2011

Clinical · 2002

Stroke Research — Registered Drug

Russian clinical research showed improved neurological recovery scores in acute ischemic stroke patients treated with SEMAX as an adjunct. This research directly informed its registration as a prescription pharmaceutical in Russia.

CNS Drug Reviews 2002

Cognition · 1997

Learning and Memory Studies

Multiple rodent studies documented improved maze performance and conditioned reflex scores. Effects attributed to BDNF upregulation and dopaminergic system modulation in hippocampal and striatal regions.

Neuroscience 1997

Handling and Storage

Storage instructions

Lyophilized powder

Store lyophilized SEMAX at −20°C. Protect from moisture and light.

After reconstitution

Once reconstituted in sterile saline or bacteriostatic water, refrigerate and use within 2–3 weeks. SEMAX is somewhat more sensitive to degradation post-reconstitution than peptides stored in bacteriostatic water.

Research Use Only. SEMAX is registered in Russia for specific medical indications. It is NOT FDA-approved. Sold for research purposes only in the United States. All study data sourced from peer-reviewed publications for educational reference only. By purchasing you confirm you are a qualified researcher. View full policy.

Your Cart

SEMAX

Three things SEMAX consistently does in studies

How SEMAX affects the brain

Published findings

Four areas with published data

What clinical and research data shows on safety

Key studies

Storage instructions

Stay Updated with Orvanta Labs